Human immunodeficiency virus (HIV) and visceral leishmaniasis (VL) are both endemic in the state of Bihar, in eastern India. With 40% of the worldwide burden of Leishmania donovani VL in Bihar [1] , plus a rising prevalence of HIV infection (currently estimated at 0.22%-0.33%) [2] and a burgeoning state population of 110 million, HIV-VL coinfection could be a growing concern for the region.
However, very limited data are available on the prevalence of coinfection in Bihar, a situation compounded by the fact that HIV testing is neither routinely performed nor required under national guidelines for patients with VL in India. Consequently, unlike the African context, coinfection is not yet viewed as a major public health issue in the Indian subcontinent [3] . This is particularly worrisome considering the poor clinical outcomes and complex treatment challenges associated with HIV-VL coinfection, which are well documented in the literature [4] .
Since 2007, Médecins Sans Frontières (MSF) has been supporting integrated diagnosis and treatment services for VL in Bihar [5] . In this study reported here, we used routinely collected program data to estimate the prevalence of HIV infection, including previously undiagnosed HIV infection, in patients ≥14 years of age presenting with VL to the MSF-supported district hospital in Vaishali, Bihar.
METHODS
Between March 2011 and October 2013, all patients presenting with clinical splenomegaly and fever of >2 weeks had a VL diagnosis confirmed by means of rK39 serological tests. Patients with suspected VL relapse, or in whom VL was suspected despite negative serological results, underwent parasitological confirmation through spleen or bone marrow biopsy. Patients were included only once in the analysis (ie, subsequent presentations within the study period were ignored).
All patients aged ≥14 years were offered provider-initiated HIV counseling and testing (PICT). Until December 2011, testing was performed by MSF using 2 rapid diagnostic tests in parallel (Determine-HIV 1/2 and SD Bioline HIV 1/2). Patients testing positive were then referred to Ministry of Health testing facilities, where Combaids Advantage, TriLine, and TriSpot rapid diagnostic tests were performed according to local diagnostic guidelines. Because of World Health Organization (WHO) concerns regarding the latter test [6] , all patients testing positive with Determine-HIV 1/2 alone were referred to Ministry of Health testing facilities. Discordant tests were confirmed using Western blot analysis. Patients reporting a previous diagnosis of HIV infection, or those referred from neighboring antiretroviral therapy (ART) centers with suspected VL, were retested for HIV but excluded from our analysis of the prevalence of previously undiagnosed HIV infection (see Supplementary Figure 1) .
Patients with confirmed HIV infection were treated for VL with liposomal amphotericin B, a treatment whose results have been described elsewhere [7] and then referred to government ART provider services for further management of HIV infection.
RESULTS
During the study period, 3615 patients had VL diagnosed at the district hospital. Of these, 2130 were ≥14 years of age and therefore eligible for PICT within the VL program. The acceptance rate for PICT was very high, at 97.5%. The 53 patients who refused PICT had no increased history of previous relapse, and their age and sex distribution reflected that of the remaining cohort. Overall, 117 (5.6%) of 2077 patients screened were HIV positive, of whom 68 had previously have HIV infection diagnosed at other facilities. The clinical and demographic characteristics of these 117 co-infected patients can be seen in the Supplementary Table 1 . Henceforth, we analyze the remaining 49 patients, for whom the program was their first point of diagnosis for both HIV infection and VL.
A higher proportion of male than female patients were found to be HIV positive (1.5-fold higher risk), although this difference did not reach threshold significance (P = .17). For male patients, HIV prevalence peaked at 5.4% in the age group of 35 to <45 years and fell steadily with either increasing or decreasing age. With the exception of a likely outlying result in the age range of 55 to <65 years (5.9%), the pattern of prevalence versus age in female patients was similar to that in male patients, although globally lower ( Figure 1 ).
Patients presenting with HIV-VL coinfection had a 3.3-fold increased relative risk (RR) of being severely anemic (hemoglobin, <6 vs >6 g/dL; P < .01). Patients presenting with HIV-VL coinfection had an 8.2-fold increased RR of previous VL episodes compared with those testing negative for HIV (P < .01). Although the difference did not reach statistical significance, patients identifying as "lower caste" and class had a lower RR of being HIV positive than those identifying as "upper caste" (0.5; P = .17). Although the RR of presenting late, having splenomegaly >6 cm, or having severe malnutrition were higher in coinfected patients than in HIVnegative patients with VL, threshold statistical significance was not reached for this difference (Table 1) .
DISCUSSION
Very limited data on the prevalence of HIV-VL coinfection in India is available in the literature [8] [9] [10] , and even less on comparative characteristics of coinfected patients [8] . The 3 previous studies conducted in India reported estimates ranging between 1.5% and 6.3%; however, all involved cohorts with <200 individuals, and none described >7 HIV-VL coinfected patients.
This retrospective observational study suggests that, although overall prevalence of undiagnosed HIV in patients ≥14 years old presenting with VL seems relatively low (2.4%), in certain age groups it is considerably higher. In our cohort, 5% of male patients 35 to <45 years old presenting with VL were unknowingly HIV positive. When pooled with data on the numbers of already-diagnosed HIV-positive patients presenting with VL to the program, altogether 12.8% and 6.1% of all 35-to <45-year-old men and women, respectively, were coinfected.
The state of Bihar has a particularly high proportion of migratory workers, but there is very little information available regarding cross-over geographic epidemiology of both diseases. The program may have treated more VL patients with a previous diagnosis of HIV infection than might be seen in other treatment centers, owing to additional referrals from one neighboring district ART center which was aware of MSFs interest in treatment and follow-up of coinfected patients. However, we c Caste is a form of social stratification used in India. Scheduled caste is a term used for a group of historically disadvantaged people recognized in the Constitution of India. Other backward class is a collective term used by the government of India for castes that are educationally and socially disadvantaged but not specifically mentioned in the Constitution. General category includes persons not considered disadvantaged, or "upper castes."
suspect that the prevalence of undiagnosed HIV infection is likely to be similar outside the nongovernmental organizational setting and in other areas of Bihar. In this cohort we did not find any obvious evidence of atypical parasite dissemination; however, this probably reflects the relatively basic diagnostic tools available within the program (rK39 rapid diagnostic test and splenic/bone marrow aspirations alone). It is more probable that a number of these patients had atypical sites of infection that were either not detected or not recognized as related to L. donovani infestation (eg, gastrointestinal symptoms).
Currently, PICT is not routinely conducted in India for patients presenting with VL, despite the WHO recommendation to offer it wherever both HIV counseling and ART are available [11] . Another contributor to missed HIV diagnoses in these patients is that, based on WHO guidelines [12] , the Indian National Agency for Control of National AIDS Control Organisation classifies only "atypical disseminated" VL, not VL in general, as a stage IV HIV/AIDS-associated illness [13] . This classification creates ambiguity about which patients with VL should be tested for HIV, given the consensus among WHO VL experts that symptomatic VL is an AIDS-defining condition and a valid entry point for starting ART, irrespective of CD4 count [11] .
These missed HIV diagnoses lead to worse outcomes from both the patient and public health perspectives. Early detection of HIV improves long-term prognosis for patients with VL, because initiation of ART has been shown to reduce mortality and VL relapse rates in India and elsewhere [7, 14] . Although still substantially worse than outcomes seen in immunocompetent patients, the results of treating coinfected patients in India with higher doses of liposomal amphotericin B are far better than those observed in East Africa, giving routine HIV testing even more importance in this setting. Simultaneously, without adequate focus on diagnosing coinfection, and considering the frequency of relapses, this group of patients may provide a continued reservoir for L. donovani, and may therefore have a role in both increasing resistance to therapeutics and limiting the success of national elimination strategies.
In conclusion, our findings suggest that HIV-VL coinfection is an underdiagnosed and underrecognized emerging public health issue in the Indian context, requiring urgent attention. Increased awareness of the relationship between the 2 diseases is important, with the development of multidisciplinary diagnosis and treatment guidelines and training modules for healthcare providers. Meanwhile, the crucial next steps include facilitation of systematic PICT for all patients with a diagnosis of VL in India, together with screening in nonendemic areas for VL of HIV-infected patients who have spent significant time in VL-endemic areas.
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